No connection

Search Results

ABBV vs ATAI

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ATAI
AtaiBeckley Inc.
BEARISH
Price
$3.69
Market Cap
$1.34B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
ATAI
--
Forward P/E
ABBV
15.42
ATAI
-7.44
P/B Ratio
ABBV
-146.66
ATAI
6.04
P/S Ratio
ABBV
6.5
ATAI
327.77
EV/EBITDA
ABBV
15.27
ATAI
-9.93

Profitability

Gross Margin
ABBV
71.46%
ATAI
0.0%
Operating Margin
ABBV
35.5%
ATAI
-3588.09%
Profit Margin
ABBV
4.0%
ATAI
0.0%
ROE
ABBV
137.96%
ATAI
-389.98%
ROA
ABBV
9.59%
ATAI
-30.75%

Growth

Revenue Growth
ABBV
9.1%
ATAI
--
Earnings Growth
ABBV
-88.7%
ATAI
--

Financial Health

Debt/Equity
ABBV
--
ATAI
0.02
Current Ratio
ABBV
0.72
ATAI
11.74
Quick Ratio
ABBV
0.47
ATAI
11.49

Dividends

Dividend Yield
ABBV
3.05%
ATAI
--
Payout Ratio
ABBV
490.15%
ATAI
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ATAI BEARISH

ATAI's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme operational weakness, and the absence of an Altman Z-Score (with negative profitability and massive losses) raises significant bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a high target price of $13.45, the company exhibits no profitability, negative margins, and a 620.8% YoY EPS decline, with earnings surprises consistently negative. The stock trades at an inflated Price/Sales of 327.77 and a Price/Book of 6.04, suggesting extreme overvaluation relative to fundamentals. Insider selling in the last six months further undermines confidence in management's view of the company's prospects.

Strengths
Analyst consensus is strongly bullish with a $13.45 target price
High market cap ($1.34B) suggests relative scale within biotech
Extremely high 1-year return (+165.5%) indicates strong momentum
Risks
Piotroski F-Score of 1/9 signals severe financial distress and operational failure
Negative ROE (-389.98%) and ROA (-30.75%) indicate deep unprofitability
Operating margin of -3588.09% reflects catastrophic cost inefficiency

Compare Another Pair

ABBV vs ATAI: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and AtaiBeckley Inc. (ATAI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile